Protocol Ledger

NCT05549258 · Phase II · RECRUITING

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Interventional Phase II clinical trial protocol NCT05549258 sponsored by Amgen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-03 Enrollment: 15 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05549258
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)15 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05549258
Protocol FieldVerified Registry Value
NCT IdentifierNCT05549258
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment15 participants (ESTIMATED)
Registered Start Date2023-07-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI